Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

Pacira BioSciences is positioned favorably because its core franchise is supported by differentiated, non-opioid products with clear reimbursement catalysts: EXPAREL has benefited from NOPAIN-related access improvements, while UNH separately reimbursing EXPAREL outside the surgical bundle for ~40MM covered lives and adding ZILRETTA broadens the commercial runway. ZILRETTA’s sales could improve with the JNJ MedTech partnership, better promotional backing, and a possible shoulder OA expansion, while EXPAREL’s 2026 revenue guidance of $600–620MM and total revenue guidance of $745–770MM suggest meaningful scale in the base business. The company’s long-term upside is amplified by PCRX-201, which has shown encouraging Phase 1 durability and safety, and by the April 2025 settlement that may extend the patent runway to 2044.

Pacira BioSciences is facing a fragile fundamental setup because EXPAREL’s growth depends heavily on reimbursement support that may weaken after December 31, 2027, while bundled-payment pressure in hospitals and uneven coverage can limit adoption in a roughly 29MM-procedure market. Its pipeline offers limited near-term offset: PCRX-201 is still in phase 2 with a year-end 2026 data readout and is viewed as a long-dated option, while iovera has only generated $24M last year, underscoring weak portfolio synergy. At the same time, patent and generic risks remain material despite the newer patent family, and any adverse litigation outcome or additional entrants could accelerate erosion of EXPAREL’s exclusivity before 2044.